Nociceptin/orphanin FQ receptor ligands

Peptides

Volumn 21, Issue 7, 2000, Pages 935-947

  Calo', Girolamo ^a   Bigoni, Raffaella ^a   Rizzi, Anna ^a   Guerrini, Remo ^a   Salvadori, Severo ^a   Regoli, Domenico ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Agonists and antagonists; Nociceptin; Nociceptin Orphanin FQ receptor; Orphanin FQ; Pharmacological assays; Receptor ligands

Indexed keywords

DYNORPHIN A; LIGAND; NALOXONE; NEUROPEPTIDE; NOCICEPTIN; NOCICEPTIN RECEPTOR; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BEHAVIOR; BRAIN; BRONCHUS; COLON; DRUG SYNTHESIS; ILEUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; VAS DEFERENS;

EID: 0033811727     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(00)00230-8     Document Type: Article

References (102)

1. Abdulla F.A., Smith P.A. Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons. J Neurosci. 18:1998;9685-9694.
2. Adam G, Cesura A, Galley G, Jenck F, Monsma F, Rover S, Wichmann J. New 8-substitute-1,3,8-triazaspiro[4.5]decan-4-on derivatives - useful for the treatment of diseases related to the Orphanin FQ receptor e.g. psychiatric, neurological and physiological disorders. EP-856514-A1, Switzerland, 1998.
3. Albrecht E., Samovilova N.N., Oswald S., Baeger I., Berger H. Nociceptin (Orphanin FQ). high-affinity and high-capacity binding site coupled to low-potency stimulation of guanylyl-5′-O-(γ-thio)- triphosphate binding in rat brain membranes. J Pharmacol Exp Ther. 286:1998;896-902.
4. Allen C.N., Jiang Z.G., Teshima K., Darland T., et al. Orphanin-FQ/nociceptin (OFQ/N) modulates the activity of suprachiasmatic nucleus neurons. J Neurosci. 19:1999;2152-2160.
5. Armstead W.M. Nociceptin/orphanin FQ dilates pial arteries by K(ATP) and k(ca) channel activation. Brain Res. 835:1999;315-323.
6. Bauer U., Nakazi M., Kathmann M., Gothert M., Schlicker E. The steroselective kappa-opioid (ORl1) receptor. Naunyn Schmiedebergs Arch Pharmacol. 359:1999;17-20.
7. Becker J.A., Wallace A., Garzon A., et al. Ligands for κ-opioid, and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem. 274:1999;27513-27522.
8. Benyhe S., Monory K., Farkas J., et al. Nociceptin binding sites in frog (Rana esculenta) brain membranes. Biochem Biophys Res Commun. 260:1999;592-596.
9. Berger H., Albrecht E., Wallukat G., Bienert M. Antagonism by acetyl-RYYRIK-NH2 of G protein activation in rat brain preparations and of chronotropic effect on rat cardiomyocytes evoked by nociceptin/orphanin FQ. Br J Pharmacol. 126:1999;555-558.
10. Berger H., Albrecht E., Wallukat G., Calo' G., Bigoni R., Bienert M. Ac-RYYRIK-NH2, a nociceptin/orphanin FQ receptor ligand, exhibits properties of an antagonist and agonist as well. Regul Pept. 80:1999;122.
11. Bertorelli R., Citterio F., Tupper J., Ongini E. Further analysis of nociceptin and derivatives following intratecal administration in mice. Regul Pept. 80:1999;122.
12. Bertorelli R., Corradini L., Rafiq K., Tupper J., Calo' G., Ongini E. Nociceptin and the putative ORL-1 ligand [Phe1psi(CH2-NH)Gly2)]nociceptin(1-13)NH2 exert anti-opiod effects in the Freund's adjuvant-induced arthritis rat model of chronic pain. Br J Pharmacol. 128:1999;1252-1258.
13. Bigoni R., Calo' G., Mitri S., Regoli D. Naloxone benzoylhydrazone acts as a nonselective nociceptin receptor antagonist. Fund Clin Pharmacol. 13:1999;214s.
14. Bigoni R., Giuliani S., Calo' G., et al. Characterization of nociceptin receptors in the periphery in vitro and in vivo studies . Naunyn Schmiedebergs Arch Pharmacol. 359:1999;160-167.
15. Bucher B. ORL1 receptor-mediated inhibition by nociceptin of noradrenaline release from perivascular sympathetic nerve endings of the rat tail artery. Naunyn Schmiedebergs Arch Pharmacol. 358:1998;682-685.
16. Butour J.L., Moisand C., Mazarguil H., Mollereau C., Meunier J.C. Recognition and activation of the opioid receptor-like ORL-1 receptor by nociceptin, nociceptin analogs and opioids. Eur J Pharmacol. 321:1997;97-103.
17. Butour J.L., Moisand C., Mollereau C., Meunier J.C. [Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 is an agonist of the nociceptin (ORL1) receptor. Eur J Pharmacol. 349:1998;R5-R6.
18. Calo' G., Bigoni R., Rizzi A., et al. Characterization of nociceptin receptors modulating locomotor activity in mice. Fund Clin Pharmacol. 13-S1:1999;S27.
19. Calo' G., Guerrini R., Bigoni R., et al. Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem. 41:1998;3360-3366.
20. Calo' G., Guerrini R., Bigoni R., et al. Characterization of [Nphe1]NC(1-13)NH2, a novel selective nociceptin receptor antagonist. Br J Pharmacol. 129:2000;1183-1193.
21. Calo' G, Rizzi A, Bigoni R, et al. The nociceptin receptor antagonist, [Nphe1]NC(1-13)NH2, reverses tolerance to systemic morphine-induced analgesia. British Pharmacological Society, Millenium Meeting, Cambridge, UK, 4-7 Jan 2000.
22. Calo' G., Rizzi A., Bodin M., et al. Pharmacological characterization of nociceptin receptor an in vitro study . Can J Physiol Pharmacol. 75:1997;713-718.
23. Calo' G., Rizzi A., Bogoni G., et al. The mouse vas deferens a pharmacological preparation sensitive to nociceptin . Eur J Pharmacol. 311:1996;R3-R5.
24. Calo' G., Rizzi A., Marzola G., et al. Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol. 125:1998;373-378.
25. Candeletti S., Guerrini R., Calo G., Romualdi P., Ferri S. Supraspinal and spinal effects of [Phe1psi(CH2-NH)Gly2]-nociceptin(1-13)-NH2 on nociception in the rat. Life Sci. 66:2000;257-264.
26. Carpenter K.J., Dickenson A.H. Evidence that [Phe1 psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2, a peripheral ORL-1 receptor antagonist, acts as an agonist in the rat spinal cord. Br J Pharmacol. 125:1998;949-951.
27. Champion H.C., Kadowitz P.J. (Tyr1)-nociceptin, a novel nociceptin analog, decreases systemic arterial pressure by a naloxone-insensitive mechanism in the rat. BBRC. 234:1997;309-312.
28. Chiou L.C. [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 activation of an inward rectifier as a partial agonist of ORL1 receptors in rat periaqueductal gray. Br J Pharmacol. 128:1999;103-107.
29. Chu X., Xu N., Li P., Mao L., Wang J.Q. Inhibition of cardiovascular activity following microinjection of novel opioid-like neuropeptide nociceptin (orphanin FQ) into the rat rostral ventrolateral medulla. Brain Res. 829:1999;134-142.
30. Chu X., Xu N., Li P., Wang J.Q. The nociceptin receptor-mediated inhibition of the rat rostral ventrolateral medulla neurons in vitro. Eur J Pharmacol. 364:1999;49-53.
31. Connor M., Vaughan C.W., Jennings E.A., Allen R.G., Christie M.J. Nociceptin, Phe(1)ψ-nociceptin(1-13), nocistatin and prepronociceptin(154-181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro. Br J Pharmacol. 128:1999;1779-1787.
32. Corbett A.D., Menzies J.R.W., Davies M.R.P., Paterson S.J. The pharmacological actions of nociceptin in the isolated colon of rat, mouse, and man. Naunyn Schmiedebergs Arch Pharmacol. 47:(358 Suppl 1):1998;40.
33. Dhawan B.N., Cesselin F., Raghubir R., et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev. 48:1996;567-592.
34. Dooley C.T., Houghten R.A. Orphanin FQ receptor binding and analog structure activity relationships in rat brain . Life Sci. 59:1996;23-29.
35. Dooley C.T., Spaeth C.G., Berzetei-Gurske I.P., et al. Binding, and In vitro activities of peptides with high affinity for the Nociceptin/Orphanin FQ receptor, ORL1. J Pharmacol Exp Ther. 283:1997;735-741.
36. Emmerson P.J., Miller R.J. Pre- and postsynaptic actions of opioid and orphan opioid agonists in the rat arcuate nucleus and ventromedial hypothalamus in vitro. J Physiol. 517:1999;431-445.
37. Gressens P., Calo' G., Evrard P. Nociceptin potentiates neonatal white matter excitotoxicity. Regul Pept. 80:1999;123.
38. Grisel J.E., Farrier D.E., Wilson S.G., Mogil J.S. [Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as an agonist of the orphanin FQ/nociceptin receptor in vivo. Eur J Pharmacol. 357:1998;R1-R3.
39. Guerrini R., Calo' G., Bigoni R., et al. Further studies on nociceptin related peptides discovery of new molecules with antagonist activity on the nociceptin receptor . Regul Pept. 80:1999;124.
40. Guerrini R., Calo' G., Rizzi A., et al. Address and message sequences for the nociceptin receptor a structure- activity study of nociceptin-(1-13)-peptide amide . J Med Chem. 40:1997;1789-1793.
41. Guerrini R., Calo' G., Rizzi A., Bigoni R., Bianchi C., Salvadori S., Regoli D. A new selective antagonist of the nociceptin receptor. Br J Pharmacol. 123:1998;163-165.
42. Hamon M. The new approach to opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 358 Suppl 1998;2:SA5.
43. Hashimoto Y., Calo' G., Guerrini R., Smith G., Lambert D.G. Antagonistic effects of [Nphe1]nociceptin(1-13)NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese ovary cells stably expressing the recombinant human nociceptin receptor. Neurosci Lett. 278:2000;109-112.
44. Hashimoto Y, Calo' G, Guerrini R, Smith G, Lambert DG. Desensitization and down-regulation of human recombinant nociceptin receptor expressed in Chinese hamster ovary cells. British Pharmacological Society, Millenium Meeting, Cambridge, UK, 4-7 Jan 2000.
45. Ho M., Watson A., Corbett A. D, McKnight A. T. characterization of the ORL1 receptor on adrenergic nerves in the anococcygeus. Br J Pharmacol. 128:1999;84P.
46. Ito F, Kondo H, Noguchi H, Ohashi Y, Yamagishi T. 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists, 1999. WO 9936421.
47. Itoh K., Konya H., Takai E., Masuda H., Nagai K. Modification of acetylcholine release by nociceptin in conscious rat striatum. Brain Res. 845:1999;242-245.
48. Jenck F., Moreau J.L., Martin J.R., et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci USA. 94:1997;14854-14858.
49. Kapusta D.R., Chang J.K., Kenigs V.A. Central administration of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. J Pharmacol Exp Ther. 289:1999;173-180.
50. Kawamoto H., Ozaki S., Itoh Y., et al. Discovery of the fist potent and selective small molecule opioid receptor-like (ORL1) antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro- 2H-benzimidazol-2-one (J-113397) . J Med Chem. 42:1999;5061-5063.
51. Kenakin T.P., Bond R.A., Bonner T.I. Definition of pharmacological receptors. Pharmacol Rev. 44:1992;351-362.
52. Lapalu S., Moisand C., Mazarguil H., Cambois G., Mollereau C., Meunier J.C. Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides. FEBS Lett. 417:1997;333-336.
53. Madamba S.G., Schweitzer P., Siggins G.R. Nociceptin Augments K(+) Currents in Hippocampal CA1 Neurons by Both ORL-1, and Opiate Receptor Mechanisms. J Neurophysiol. 82:1999;1776-1785.
54. Madeddu P., Salis M.B., Milia A.F., et al. Cardiovascular effects of nociceptin in unanesthetized mice. Hypertension. 33:1999;914-919.
55. Malinowska B., Kozlowska H., Koneczny B., Schlicker E. Nociceptin inhibits the neurogenic vasopressor response in the pithed rat via prejunctional ORL1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 361:2000;80-84.
56. Mamiya T., Noda Y., Nishi M., Takeshima H., Nabeshima T. Nociceptin system plays a role in the memory retention involvement of naloxone benzoylhydrazone binding sites . Neuroreport. 10:1999;1171-1175.
57. Maneuf YP, Hughes J, McKnight AT. Different actions of ORL1 agonists on K+-evoked [3H]-5-HT release from rat cortical slices. Soc Neurosci, Vol. 25, 1999;172:6.
58. Mason SL, Nicholson JR, Lee K, McKnight AT. The effect of the agonist ac-RYYRWK-NH2 and the antagonist [Phe1psi(CH3NH)Gly2]NC(1-13)NH2 at the ORL1 receptors of central and peripheral sites. Soc Neurosci, Vol. 24, 1998;536:20.
59. Meis S., Pape H.C. Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to Nociceptin/Orphanin FQ. J Neurosci. 18:1998;8133-8144.
60. Meunier J.C. Nociceptin/orphanin FQ, and the opioid receptor-like ORL1 receptor. Eur J Pharmacol. 340:1997;1-15.
61. Mollereau C., Parmentier M., Mailleux P., et al. ORL1, a novel member of the opioid receptor family - cloning, functional expression and localization. FEBS Lett. 341:1994;33-38.
62. Narita M., Mizoguchi H., Oji D.E., et al. Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPγS binding and immunohistochemistry. Br J Pharmacol. 128:1999;1300-1306.
63. Nicholson JR, Mason SL, Lee K, McKnight AT. The effect of the agonist Ac-RYYRWKNH2 and the antagonist [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 at the ORL1 receptor of central and peripheral sites., 29th International Narcotics Research Conference, A129, Garmisch-Partenkirchen (Germany), 20-25 July 1998.
64. Nicholson JR, Paterson SJ, McKnight AT. Characterization of the response in the rat vas deferens to the ORL-1 agonist nociceptin. Br J Pharmacol 119 Proceeding Suppl 1996;36P.
65. Nicholson J.R., Paterson S.J., Menzies J.R., Corbett A.D., McKnight A.T. Pharmacological studies on the "orphan" opioid receptor in central and peripheral sites. Can J Physiol Pharmacol. 76:1998;304-313.
66. Nicol B., Okawa H., Rowbotham D.J., Lambert D.G. Effects of naloxone benzoylhydrazone on nociceptin signalling in rat brain and CHO cells expressing recombinant nociceptin receptors. Regul Pept. 80:1999;125.
67. Noda Y., Mamiya T., Nabeshima T., Nishi M., Higashioka M., Takeshima H. Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice. J Biol Chem. 273:1998;18047-18051.
68. Okawa H., Nicol B., Bigoni R., et al. Comparison of the effects of Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin recetors. Br J Pharmacol. 127:1999;123-130.
69. Olianas M.C., Maullu C., Ingianni A., Onali P. [Phe1phi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as a partial agonist at ORL1 receptor endogenously expressed in mouse N1E-115 neuroblastoma cells. Neuroreport. 10:1999;1127-1131.
70. Ozaki S, Kawamoto H, Ito Y, Hayashi K, Iwasawa Y, Hirano K., New 2-oxoimidazole derivatives - are nociceptin receptor binding inhibitors useful e.g. as analgesics and for amelioreting brain function. Japan, 1998.
71. Paul D., Levison J.A., Howard D.H., Pick C.G., Hahn E.F., Pasternak G.W. Naloxone benzoylhydrazone (NalBzoH) analgesia. J Pharmacol Exp Ther. 255:1990;769-774.
72. Pheng L., Calo' G., Guerrini R., Regoli D. [Nphe(1)]nociceptin-(1-13)NH(2) selectively antagonizes nociceptin effects in the rabbit isolated ileum. Eur J Pharmacol. 397:2000;383-388.
73. Polidori C., Calo' G., Ciccocioppo R., Guerrini R., Regoli D., Massi M. Pharmacological characterization of the nociceptin receptor mediating hyperphagia identification of a selective antagonist . Psychopharmacology. 148:2000;430-437.
74. Polidori C., Calo' G., deCaro G., Regoli D., Pompei P., Massi M. Sensitivity of brain sites to the orexigenic effect of nociceptin or its analog [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2. Regul Pept. 80:1999;126.
75. Pu L., Bao G.B., Ma L., Pei G. Acute desensitization of nociceptin/orphanin FQ inhibition of voltage-gated calcium channels in freshly dissociated hippocampal neurons. Eur J Neurosci. 11:1999;3610-3616.
76. Reinscheid R.K., Ardati A., Monsma F.J. Jr, Civelli O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J Biol Chem. 271:1996;14163-14168.
77. Reinscheid R.K., Higelin J., Henningsen R.A., Monsma F.J. Jr, Civelli O. Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities. J Biol Chem. 273:1998;1490-1495.
78. Rizzi A., Bigoni R., Calo' G., Guerrini R., Salvadori S., Regoli D. [Nphe1]nociceptin(1-13)NH2 antagonizes nociceptin effects in the mouse colon. Eur J Pharmacol. 385:1999;R3-R5.
79. Rizzi A., Calo' G., Trevisani M., et al. Nociceptin receptor activation inhibits tachykinergic nonadrenergic noncholinergic contraction of guinea pig isolated bronchus. Life Sci. 64:1999;L157-L163.
80. Salvadori S., Picone D., Tancredi T., et al. Solution conformation of nociceptin. Biochem Biophys Res Commun. 233:1997;640-643.
81. Sandin J., Georgieva J., Silberring J., Terenius L. In vivo metabolism of nociceptin/orphanin FQ in rat hippocampus. Neuroreport. 10:1999;71-76.
82. Sbrenna S., Marti M., Morari M., et al. 5-HT efflux from rat cerebrocortical synaptosomes modulation by opioids and nociceptin . Br J Pharmacol. 130:2000;425-433.
83. Sbrenna S., Marti M., Morari M., et al. 5-HT, Glu and GABA efflux from rat cerebrocortical synaptosomes modulation by opioid receptor like 1 receptor . Regul Pept. 80:1999;127.
84. Schlicker E., Werthwein S., Kathmann M., Bauer U. Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors. Naunyn-Schmiedeberg's Arch Pharmacol. 358:1998;418-422.
85. Seki T., Awamura S., Kimura C., et al. Pharmacological properties of TRK-820 on cloned μ-, δ- and κ- opioid receptors and nociceptin receptor. Eur J Pharmacol. 376:1999;159-167.
86. Shah S., Page C.P., Spina D. Nociceptin inhibits non-adrenergic non-cholinergic contraction in guinea-pig airway. Br J Pharmacol. 125:1998;510-516.
87. Shimohigashi Y., Hatano R., Fujita T., et al. Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide. J Biol Chem. 271:1996;23642-23645.
88. Siniscalchi A., Rodi D., Beani L., Bianchi C. Inhibitory effect of nociceptin on [3H]5-HT release from the rat cerebral cortex slices. Br J Pharmacol. 128:1999;119-123.
89. Siniscalchi A., Sbrenna S., Rodi D., Beani L., Bianchi C. Inhibitory effect of nociceptin on [3H]5-HT release from the rat cerebral cortex in vitro. Br J Pharmacol. 126:1999;266P.
90. Sulaiman M.R., Niklasson M., Tham R., Dutia M.B. Modulation of vestibular function by nociceptin/orphanin FQ an in vivo and in vitro study . Brain Res. 828:1999;74-82.
91. Toll L, Burnside J, Berzetei-Gurske I. Agonist activity of ORL1 antagonists is dependent upon receptor number. International Narcotics Research Conference 1998;Garmisch-Partenkirchen:Germany,20-25 July, 1998, A89.
92. Topham C.M., Mouledous L., Poda G., Maigret B., Meunier J.C. Molecular modelling of the ORL1 receptor and its complex with nociceptin. Protein Eng. 11:1998;1163-1179.
93. Varani K., Calo' G., Rizzi A., et al. Nociceptin receptor binding in mouse forebrain membranes thermodynamic characteristics and structure activity relationships . Br J Pharmacol. 125:1998;1485-1490.
94. Varani K., Rizzi A., Calo' G., et al. Pharmacology of [Tyr1]nociceptin analogs receptor binding and bioassay studies . Naunyn Schmiedebergs Arch Pharmacol. 360:1999;270-277.
95. Wang Y.Q., Zhu C.B., Cao X.D., Wu G.C. Supraspinal hyperalgesia and spinal analgesia by [Phe1psi(CH2- NH)Gly2]nociceptin-(1-13)-NH2 in rat. Eur J Pharmacol. 376:1999;R1-R3.
96. Wichmann J., Adam G., Rover S., Cesura A.M., Dautzenberg F.M., Jenck F. 8-Acenaphthen-1-YL-1-phenyl-1,3,8-triaza-spiro[4,5]decan-4-one derivatives as orphanin fq receptor agonists. Bioorg Med Chem Lett. 9:1999;2343-2348.
97. Wnendt S., Kruger T., Janocha E., Hildebrandt D., Englberger W. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol. 56:1999;334-338.
98. Xu I.S., Wiesenfeld-Hallin Z., Xu X.J. [Phe1psi(CH2-NH)Gly2]-nociceptin-(1-13)NH2, a proposed antagonist of the nociceptin receptor, is a potent and stable agonist in the rat spinal cord. Neurosci Lett. 249:1998;127-130.
99. Yakimova K.S., Pierau F.K. Effect of nociceptin and [Phe1psi (CH2-NH) Gly2]-nociceptin-(1-13)-NH2 on tonic activity of rat hypothalamic neurons. Neurosci Lett. 274:1999;87-90.
100. Yoshikawa M, Takahashi M, Yunden J. Analgesic and cognition-enhancing activity of retronociceptin methyl-ester, a nociceptin antagonist. International Narcotics Research Conference, Saratoga Springs, NY, July 10-15, 1999, Sun63.
101. Zadina J.E., Hackler L., Ge L.J., Kastin A.J. A potent and selective endogenous agonist for the μ opiate receptor. Nature. 386:1997;499-502.
102. Zgodzinski W, Rubaj A, Gustaw K, Sieklucka-Dziuba M, Kleinrok Z., Anticonvulsant effects of orphanin FQ receptor ligands. International Narcotics Research Conference, Saratoga Springs, NY, July 10-15, 1999. Sun70.